Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel/prednisolone with or without vandetanib in hormone refractory prostate cancer
2005-003593-16Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in prostate cancer (PCa) comparing Docetaxel + prednisolone + ZACTIMA with Docetaxel + prednisolone + placebo (2 arms). Primary endpoint: PSA response rate. Started Oct 2005; status: completed.
02
Drugs
vandetanib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2005-003593-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003593-16.